Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

Exclusion Criteria

• •The following WHO 2016 subcategories by local assessment:
• •* T-cell/histiocyte-rich LBCL
• •* Primary DLBCL of the central nervous system (CNS)
• •* Primary mediastinal (thymic) LBCL
• •* B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma
• •* Burkitt lymphoma
• •* History of Richter's transformation of chronic lymphocytic leukemia
• •Presence of detectable cerebrospinal fluid (CSF)-malignant cells, brain metastases, or a history of CNS involvement of lymphoma.
• •Presence of cardiac lymphoma involvement.
• •Any prior treatment for LBCL other than the 1 cycle of R-chemotherapy.
• •History of severe immediate hypersensitivity reaction to any of the agents used in this study.
• •Presence of CNS disorder. History of stroke, transient ischemic attack, or posterior reversible encephalopathy syndrome (PRES) within 12 months prior to enrollment.
• •History of acute or chronic active hepatitis B or C infection.
• •Positive for human immunodeficiency virus (HIV) unless taking appropriate anti-HIV medications, with an undetectable viral load by PCR and with a cluster of differentiation 4 (CD4) count \> 200 cells/uL.
• •Medical conditions or residual toxicities from prior therapies likely to interfere with assessment of safety or efficacy of study treatment. Please refer to protocol for further details.
• •History of clinically significant cardiac disease within 12 months before enrollment.
• •History of any medical condition requiring maintenance systemic immunosuppression/systemic disease modifying agents within the last 2 years.